J. Molner announces that it has signed a Product Development Agreement with a U.S.-based pharmaceutical partner. This agreement marks another milestone in Molner’s strategic expansion within the U.S. generic pharmaceutical market.

Under the agreement, J. Molner will lead the development of a new generic pharmaceutical product for the U.S. market, with the partner providing financial support of USD 1.8 million over the next twelve months and sharing in the product’s commercial success through a structured profit-sharing arrangement.

As part of this collaboration, Sten Akel, CFO of J. Molner, commented: “We are pleased to work with our U.S. partner to bring a new generic alternative to market. This collaboration not only aligns with our mission to provide affordable healthcare solutions but also strengthens our footprint in the competitive U.S. market. ”

Under the terms of the agreement, J. Molner will manage all aspects of development, regulatory submissions, and manufacturing preparations. Upon U.S. Food and Drug Administration (FDA) approval, J. Molner will oversee commercialization efforts in the U.S.

This agreement is part of Molner’s broader strategy to expand its product portfolio in the U.S. market through strategic partnerships. The company remains committed to innovation and excellence in the pharmaceutical industry, reinforcing its position as a trusted leader in complex generics.

For additional information about J. Molner, please visit www.jmolner.com